Lupin is amongst the few Indian pharmaceutical companies with a single-minded focus on the marketplace and brand building. Lupin has specific market focus with an identified product pipeline for each market of the world.
In advanced market, focus is on niche opportunities and on NDDS with a view to provide superior compliance benefits, enabling shift from “generics” to “super generics” to “branded”.
In developing markets there is growing focus on life-style induced disease, exploring in-licensing opportunities and increase CIS presence.
Our forte lies in the anti-Tuberculosis, cephalosporins, cardiovascular, anti-asthma, Non-steroidal anti-inflammatory drugs.
Lupin is among the few companies from India with global scale manufacturing facilities that measure up to world's best quality standards. Nine of Lupin's manufacturing facilities have been approved by the USFDA.
Know about product details of our markets in:
India
Rest of World (ROW)
US & Europe
|
